A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment

Inclusion Criteria Concurrent Medication: Allowed: * Erythropoietin and G-CSF. Concurrent Treatment: Allowed: * Local skin radiotherapy. Patients must have: * HIV infection. * CD4 count 50 - 350 cells/mm3. * No prior antiretroviral therapy OR less than 16 weeks of prior AZT. * No acute serious opportunistic infections requiring immediate treatment. * No unexplained fever persisting for 14 days within 90 days prior to study entry. * No significant unexplained diarrhea persisting for 14 days within 30 days prior to study entry. * No visceral Kaposi's sarcoma or lymphoma currently requiring chemotherapy and/or radiotherapy. * Life expectancy of at least 80 weeks. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Malabsorption. * Severe chronic diarrhea. * Inadequate oral intake (unable to eat one or more meals daily because of chronic nausea, emesis, or abdominal/oral-esophageal discomfort). * Any grade 3 or worse toxicity. * Inability to comply with study requirements. Concurrent Medication: Excluded: * Other investigational agents. * Antineoplastic agents. * Biologic response modifiers (including interferons). * Foscarnet. * Anti-HIV drugs other than the study drugs. Concurrent Treatment: Excluded: * Radiotherapy (other than local skin radiotherapy). Patients with the following prior condition are excluded: History of non-Hodgkin's lymphoma. Prior Medication: Excluded: * Acute therapy for opportunistic infection within 14 days prior to study entry. * Prior HIV proteinase inhibitor.